AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD

Grant

Date/time Interval

  • March 5, 2014 - September 4, 2014
  • Total Award Amount

  • 21200.00
  • Direct Costs

  • 16825.00
  • Sponsor Award Id

  • Contributor

  • Bemrich-Stolz, Christina   Investigator  
  • Friedman M.D., Gregory   Investigator  
  • Hilliard, Lee   Investigator  
  • Howard, Thomas   Investigator  
  • Kutny M.D., Matthew   Investigator  
  • Lebensburger, Jeffrey   Investigator  
  • Whelan M.D., Kimberly   Investigator